Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study

BACKGROUND: Immunotherapy represented by PD-1 blockades had become the standard of care for advanced non-small cell lung cancer (NSCLC) gradually. Unfortunately, several PD-1 inhibitor-related studies excluded elderly patients with NSCLC over 75 years of age, resulting in relatively limited evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao-Ping, Zhang, Wei-Dong, Li, Ming-Jiang, Wang, Juan, Lian, Jie, Zhou, Hong-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337937/
https://www.ncbi.nlm.nih.gov/pubmed/35909903
http://dx.doi.org/10.1155/2022/1710272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337937/
https://www.ncbi.nlm.nih.gov/pubmed/35909903
http://dx.doi.org/10.1155/2022/1710272

Ejemplares similares